Investigation of favipravir side effects in the treatment of SARS COV2

Abstract

The frightening speed at which the COVID-19 pandemic is spreading around the world has shown us how few antiviral drug options we have available. Currently, the COVID-19 pandemic is almost in its second year, and favipiravir is an important antiviral agent still used in the first line of treatment. It is thought that there is a need for more advanced studies on the use of SARS COV2, as this drug, which has recently had disagreements about its use, day by day. However, the literature information on the side effects of this drug is limited, and the frequency of side effects and the mechanism of action have not been fully explained. A study conducted in Japan found that approximately 20% of patients receiving low-dose favipiravir experienced side effects. Although with low frequency, hyperuricemia, diarrhea and neutropenia, and psychiatric symptoms and teratogenicity are mostly mentioned. The effect of favipiravir on corrected QT interval prolongation is still unclear. Overall, in fact, favipiravir has a good safety profile, as confirmed by a large systematic review. We aimed to contribute to this study by reviewing the side effects of favipiravir in the light of the literature due to a lot of information that is still unclear.

Keywords

• SARS COV 2
• favipiravir
• COVID 19

SARS COV2 tedavisinde favipiravir yan etkilerinin araştırılması

Abstract

COVID-19 pandemisinin dünyaya yayılma hızındaki korkutucu hız, bize mevcut antiviral ilaç seçeneklerimizin ne kadar az olduğunu gösterdi. Şu an COVID-19 pandemisi neredeyse ikinci yılını doldurmak üzeredir ve favipiravir tedavide ilk basamakta halen kullanılan önemli bir antiviral ajandır. Son dönemde, özellikle kullanımı konusunda fikir ayrılıkları yaşanan bu ilacın, gün geçtikçe, SARS CoV2 tedavisinde kullanımı hakkında daha çok çalışmaya ihtiyaç olduğu düşünülmektedir. Ancak literatürde, bu ilaç ile ilgili yan etki bilgileri sınırlı olup yan etki sıklığı ve etki mekanizması tam olarak açıklanamamıştır. Japonya’da yapılan bir çalışmada, düşük doz favipiravir alan hastaların yaklaşık %20'sinde yan etkilerin görüldüğü bulunmuştur. Seyrek olmakla birlikte en çok hiperürisemi, diyare, nötropeni ve psikiyatrik semptomlar ile teratojeniteden bahsedilmektedir. Favipiravirin düzeltilmiş QT mesafesi uzamasındaki etkisi ise hala belirsizdir. Genel olarak, aslında favipiravir, geniş bir sistematik incelemeyle onaylandığı gibi iyi bir güvenlik profiline sahiptir. Hala net olmayan birçok bilgi sebebi ile favipiravirin yan etkilerini literatür ışığında gözden geçirerek bu çalışmaya katkı sağlamayı amaçladık.

Keywords

• SARS COV2
• Favipiravir
• COVID-19

Supporting Institution

yok

References

1. 1. Alkan Çeviker S, Dindar Demiray E. SARS-CoV-2 (COVİD 19 ) enfeksiyonu ayırıcı tanı açısından diğer solu-numsal virüsler. J Biotechinol & Strategic Health Res 2020; 4: 45-49.
2. 2. Şener A. COVİD-19 (SARS Cov-2) tedavisi. J Biotec-hinol & Strategic Health Res 2020; 4: 97-104.
3. 3. Alıravcı I, Çetinkaya C, Alkan Çeviker S. Antiviral tedavi almadan spontan iyileşen astım ve COVID 19 pnö-molili hastanın üç aylık takibi. BSJ Health Sci 2021; 4(2): 150-152.
4. 4. Cai Q, Yang M, Liu D, et al. Experimental treatment with favipiravir for COVID-19: An open-label control study. Engineering (Beijing) 2020 Oct;6(10):1192-1198.
5. 5. T.C. Sağlık Bakanlığı COVID19 Tanı ve Tedavi Rehbe-ri. https://covid19bilgi.saglik.gov.tr/depo/rehberler/ COVID-19_Rehberi.pdf. Erişim 15 Eylül 2021.
6. 6. Furuta Y, Komeno T, Nakamura T. Favipiravir (T-705), a broad spectrum inhibitor of viral RNA polymerase. Proc Jpn Acad Ser B Phys Biol Sci 2017;93(7):449-463.
7. 7. Şimşek Yavuz S, Ünal S. Antiviral treatment of COVID-19. Turk J Med Sci 2020;50(SI-1):611‐619.
8. 8. Jordan PC, Stevens SK, Deval J. Nucleosides for the treatment of respiratory RNA virus infections. Antivir Chem Chemother 2018;26:2040206618764483.

9. 9. Doğan E, Alkan-Çeviker S, Vurucu S, et al. Investiga-tion of the frequency of adverse effects in patients treated with favipiravir as SARS-CoV-2 treatment. Klimik Derg 2021; 34(2): 95-98.
10. 10. Shrestha DB, Budhathoki P, Khadka S, Shah PB, Pokharel N, Rashmi P. Favipiravir versus other antiviral or standard of care for COVID-19 treatment: a rapid systema-tic review and meta-analysis. Virol J 2020;17(1):141.
11. 11. Ivashchenko AA, Dmitriev KA, Vostokova NV, et al. AVIFAVIR for treatment of patients with moderate COVID-19: Interim results of a phase II/III multicenter randomized clinical trial. Clin Infect Dis 2021; 73(3): 531-534.
12. 12. Chen C, Zhang Y, Huang J, et al. Favipiravir versus arbidol for COVID-19: A randomized clinical trial. medRxiv: 2020.03.17.20037432.
13. 13. Avigan Tablets 200 mg. https://www.cdc.gov. tw/File/ Get/ht8jUiB_MI-aKnlwstwzvw. Erişim 10 Temmuz 2021.
14. 14. Pilkington V, Pepperrell T, Hill A. A review of the safety of favipiravir: A potential treatment in the COVID-19 pandemic? J Virus Erad 2020;6(2):45-45.
15. 15. Sanders JM, Monogue ML, Jodlowski TZ, Cutrell JB. Pharmacologic treatments for coronavirus disease 2019 (COVID-19): A review. JAMA. 2020;323(18):1824-1836.
16. 16. Bouazza N, Treluyer JM, Foissac F, et al. Favipiravir for children with Ebola. Lancet 2015;385(9968):603-604.
17. 17. Guidelines for the management of pregnant and breast-feeding women in the context of Ebola virus disease. Gene-va: World Health Organization; 2020 Feb. https://www.ncbi.nlm.nih.gov/books/NBK554101. Erişim 10 Eylül 2021.
18. 18. Alıravcı I, Alkan Çeviker S. COVID-19 karaciğer tutulumu ve altta yatan karaciğer hastalığı olanlarda hastalık seyrinin irdelenmesi: Derleme. Journal of Biotechnology and Strategic Health Research 2020; 4(3): 206-211.
19. 19. İzci-Çetinkaya F, Karagöz H, Yıldız O. Comparison of liver safety of favipiravir and hydroxychloroquine in COVID-19 treatment. Klimik Derg 2020; 33(3): 235-240.
20. 20. Eroğlu E, Tarakçı A, Çölkesen F, Şengöz M, Kacar F, Özdemir Ş. COVID-19 Hastalarında lopinavir/ritonavir ve favipravir deneyimi. J Contemp Med 2020; 10(4): 642-646.
21. 21. Chinello P, Petrosillo N, Pittalis S, Biava G, Ippolito G, Nicastri E; INMI Ebola Team. QTc interval prolongation during favipiravir therapy in an Ebolavirus-infected patient. PLoS Negl Trop Dis 2017;11(12):e0006034.
22. 22. Naksuk N, Lazar S, Peeraphatdit TB. Cardiac safety of off-label COVID-19 drug therapy: A review and proposed monitoring protocol. Eur Heart J Acute Cardiovasc Care 2020;9(3):215-221.
23. 23. Elfiky AA. Ribavirin, remdesivir, sofosbuvir, galidesi-vir, and tenofovir against SARS-CoV-2 RNA dependent RNA polymerase (RdRp): A molecular docking study. Life Sci 2020;253:117592.
24. 24. Cianfrone G, Pentangelo D, Cianfrone F, et al. Pharma-cological drugs inducing ototoxicity, vestibular symptoms and tinnitus: A reasoned and updated guide. Eur Rev Med Pharmacol Sci 2011;15(6):601-636.
25. 25. Ciorba A, Corazzi V, Skarżyński PH, et al. Don't forget ototoxicity during the SARS-CoV-2 (Covid-19) pandemic! Int J Immunopathol Pharmacol. 2020;34:20587384209417 54.
26. 26. Plasencia-García BO, Rodríguez-Menéndez G, Rico-Rangel MI, Rubio-García A, Torelló-Iserte J, Crespo-Facorro B. Drug-drug interactions between COVID-19 treatments and antipsychotics drugs: Integrated evidence from 4 databases and a systematic review. Psychopharma-cology (Berl). 2021;238(2):329-340.
27. 27. Alkan Çeviker S, Şener A, Yüksel C , et al. Angioede-ma and acute urticaria in a patient with COVID 19 pneu-monia: Favipiravir side effect or COVID-19 cutaneous manifestation. Journal of Emergency Medicine Case Re-ports 2021; 12(2): 65-67.
28. 28. Hassanipour S, Arab-Zozani M, Amani B, Heidarzad F, Fathalipour M, Martinez-de-Hoyo R. The efficacy and safety of Favipiravir in treatment of COVID-19: A syste-matic review and meta-analysis of clinical trials. Sci Rep 2021;11(1):11022.